Futures slip, bank earnings ahead, Powell to speak - what’s moving markets
Justin J. Noznesky, Chief Marketing & Strategy Officer at AtriCure, Inc. (NASDAQ:ATRC), sold 3,000 shares of common stock on September 12, 2025, for a total of $108,899.
The shares were sold at prices ranging from $36.28 to $36.36, with a weighted average sales price of $36.30. Following the transaction, Noznesky directly owns 83,964 shares of AtriCure . The company maintains strong liquidity with a current ratio of 3.94 and operates with moderate debt levels. Discover more exclusive insights and detailed analysis in the comprehensive Pro Research Report, available with an InvestingPro subscription.
In other recent news, AtriCure reported its second-quarter 2025 financial results, surpassing consensus expectations for revenue, EBITDA, and earnings per share. The company posted a revenue increase to $136.1 million, exceeding forecasts of $130.17 million, and an EPS of -$0.13, which was better than the anticipated -$0.17. This performance led AtriCure to raise its full-year 2025 guidance for revenue, adjusted EBITDA, and EPS. Needham responded by raising its price target for AtriCure to $45.00 from $44.00, maintaining a Buy rating on the stock. JMP Securities also reiterated its Market Outperform rating with a $60.00 price target after noting a 17% year-over-year sales growth. AtriCure’s adjusted EBITDA nearly doubled to $15.4 million, significantly exceeding the Street’s expectation of $10 million. These developments reflect positive analyst sentiment and investor confidence in the company’s strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.